Article
SCGB1A1 as a novel biomarker and promising therapeutic target for the management of HNSCC
3 Sept 2024
Abstract excerpt
Head and neck cancer (HNC) is the sixth most common type of cancer worldwide, and head and neck squamous cell carcinoma (HNSCC) accounts for 90% of HNC cases. Furthermore, HNSCC accounts for 400,000 cancer‑associated deaths worldwide each year. However, at present there is an absence of a versatile biomarker that can be used for diagnosis, prognosis evaluation and as a therapeutic target for HNSCC. In the present...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
